Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on developing next-generation cell and gene therapies using proprietary gene circuit technology. The company went public in June 2022 through a de-SPAC merger with Dynamics Special Purpose Corp., a blank-check vehicle sponsored by Dynamics Capital Group that completed its IPO in 2021. Senti operates in the biotechnology sector, with its gene circuit platform designed to engineer therapeutic cells capable of sensing and responding to complex disease signals, with a primary focus on oncology. The company filed an 8-K with the SEC on September 2, 2026. Sign up for a free SpacDesk account to access the full filing history, deal analytics, and real-time alerts for SNTI and hundreds of other SPAC-derived companies.